NCT03051256Phase 2Completed

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Study sponsor: Relmada Therapeutics, Inc. · RLMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2019-07-30Actual
Enrollment · participants62Actual
Source updated2023-11-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.